Premium
Angiosarcoma successfully treated with liver transplantation and sirolimus
Author(s) -
Xue Megan,
Masand Prakash,
Thompson Patrick,
Finegold Milton,
Leung Daniel H.
Publication year - 2014
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12245
Subject(s) - sirolimus , medicine , angiosarcoma , transplantation , chemotherapy , liver transplantation , cancer research , population , pi3k/akt/mtor pathway , discovery and development of mtor inhibitors , oncology , pathology , apoptosis , biochemistry , environmental health , chemistry
Malignant liver tumors represent approximately 1% of malignancies in children. HA is a high‐grade tumor of endothelial cells that is even more rare in the pediatric population. HA has a limited response to chemotherapy, radiation and resection with universal tumor recurrence with LT and nearly 100% mortality by 18 months. This is the first reported successful case of hepatic angiosarcoma in a child who was treated by LT in combination with sirolimus. Sirolimus antagonizes the mTOR pathway, which regulates cell proliferation, differentiation, and migration, and is being studied as an anti‐neoplastic agent for solid tumors.